Back to Search
Start Over
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
- Source :
- The Lancet Diabetes & Endocrinology. 11:169-181
- Publication Year :
- 2023
- Publisher :
- Elsevier BV, 2023.
- Subjects :
- Endocrinology
Endocrinology, Diabetes and Metabolism
Internal Medicine
Subjects
Details
- ISSN :
- 22138587
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- The Lancet Diabetes & Endocrinology
- Accession number :
- edsair.doi...........638b3023bf6270d435d07dc7729ed160
- Full Text :
- https://doi.org/10.1016/s2213-8587(22)00387-4